Sjögren Syndrome Clinical Trial
Official title:
Investigation of the Effects of Pelvic Floor Exercises on Pain, Sexual Dysfunction and Quality of Life in Female Patients With Sjögren
Verified date | October 2022 |
Source | Akdeniz University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
When the literature is examined, the positive effects of pelvic floor exercises on sexual functions have been supported by studies. However, the effectiveness of pelvic floor exercises on pelvic floor problems in women with sjögren has not been examined in the literature. The aim of this study is in order to examine the effect of pelvic floor exercises on sexual function in women with primer Sjögren Syndrome (pSS), since these negativities affect both the quality of life and sexual functions in women with pSS. This is a randomized controlled trial examining the effect of 8 weeks of home-based pelvic floor exercises on pain, sexual dysfunction and quality of life on women with sjogren's.
Status | Completed |
Enrollment | 46 |
Est. completion date | August 15, 2022 |
Est. primary completion date | August 15, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Be woman - Having a diagnosis of primary sjogren's - No comorbidities other than Sjögren's syndrome - Not having had pelvic floor surgery - Being sexually active - Voluntary and consent to participate in the study Exclusion Criteria: - Other rheumatological diseases - Urogynecological diseases - Sarcoidosis - lymphoma - Having had a non-cesarean gynecological operation - Infection |
Country | Name | City | State |
---|---|---|---|
Turkey | Antalya Training and Research Hospital | Antalya |
Lead Sponsor | Collaborator |
---|---|
Akdeniz University |
Turkey,
Bø K, Talseth T, Vinsnes A. Randomized controlled trial on the effect of pelvic floor muscle training on quality of life and sexual problems in genuine stress incontinent women. Acta Obstet Gynecol Scand. 2000 Jul;79(7):598-603. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pelvic Pain Impact Questionnaire | The clinical assessment of the impact of pelvic pain on women questionnaire consists of 10 questions. The first 8 questions of the questionnaire are in the form of Likert type and are scored between 0-4. The total score is reached by adding the scores given for each item, and the last two questions are not included in the calculation. | 8 weeks | |
Primary | Visual Analog Scale (VAS) | It is used to convert some values that cannot be measured numerically. Two end definitions of the parameter to be evaluated are written at the two ends of a 100 mm line, and the patient is asked to indicate where on this line their situation is appropriate by drawing a line or by placing a dot or pointing. For example, for pain, I have no pain at one end and very severe pain at the other end and the patient marks his/her current state on this line. The length of the distance from the point where there is no pain to the point marked by the patient indicates the patient's pain. | 8 weeks | |
Primary | Pelvic Floor Distress Scale-20 | Scale is a 20-item symptom questionnaire used to measure the degree of discomfort caused by pelvic symptoms in women. Each item consists of 4 options (Never, Rarely, Moderately, Quite often) and is scored between 1 and 4. PFDI consists of 3 sub-dimensions: Urinary distress inventory, Colo-rectal-anal distress inventory, Pelvic organ prolapse distress inventory. The mean scores of the items in each sub-dimension are calculated and these scores are multiplied by 25 and PFDI subscale scores ranging from 0-100 are calculated. Then, the 3 subscale scores are summed to find the PFDI total score, which ranges from 0-300. A higher score indicates worse health. | 8 weeks | |
Primary | Female Sexual Function Inventory | This scale consists of 19 items and is a Likert type scale that evaluates sexual dysfunction in women. The validity and reliability study of FSFI was conducted by Rosen et al. (2000). The Turkish validity and reliability analysis of the scale was performed by Öksüz and Malhan (2005). The scale consists of six separate headings: desire, arousal, lubrication, orgasm, sexual success and pain. Each title is scored 0 or between 1 and 6. The lowest score is two (2) and the highest score is thirty-six (36). A higher score means better function. If the FSFI score is >30, it is classified as good, between 23-29 as moderate, and <23 as bad. | 8 weeks | |
Secondary | Pelvic floor impact questionnaire-7 | This scale evaluates the effects of bladder, bowel and pelvic organ symptoms on an individual's activities of daily living, social relationships and emotions. Pelvic organ prolapse impact questionnaire (POPIQ-7); urinary effects questionnaire (IIQ-7); and the colorectal-anal effect questionnaire (CRAIQ-7). Each section consists of 7 questions. The questions are scored between 0 and 3 (not at all, slightly affected, moderately affected, highly affected). When calculating the total score, the average of each scale is calculated separately, multiplied by 100 and divided by 3. The scores found are summed up. The total score ranges from 0 to 300, with a low score indicating less impact of symptoms on quality of life. | 8 weeks | |
Secondary | Health Assessment Questionnaire | This scale is consisting of 20 questions used to question functional disability and physical disability. A high score from the scale indicates low functionality. Each item is scored between 0-3 (0: I do it with no difficulty; 1: I do it with some difficulty; 2: I do it with great difficulty; 3: I can't do it at all). In addition, the use of assistive devices and the help requested from another person are also taken into account in the scoring. The sections that make up the scale are dressing, straightening, eating, walking, hygiene, reaching, grasping and daily tasks, and each section contains two or three items. Each section is scored separately, and a single HAQ score, which can vary between 0-3, is determined by taking the average of the scores of the 8 sections. In scoring the sections, the highest score among the items forming that section is accepted as the section score. | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02752269 -
Early Detection of Pulmonary- and Pulmonary Vascular Disease in Sjögren Syndrome
|
||
Completed |
NCT03905525 -
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome
|
Phase 2 | |
Completed |
NCT04819269 -
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
|
Phase 3 | |
Completed |
NCT02011776 -
A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome
|
N/A | |
Recruiting |
NCT06411132 -
Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye
|
||
Completed |
NCT03762824 -
Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease
|
Phase 4 | |
Terminated |
NCT04035668 -
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
|
Phase 2 | |
Completed |
NCT02049112 -
A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study
|
Phase 4 | |
Recruiting |
NCT04848870 -
Dental and Periodontal Status of Patients With Sjögren's Syndrome.
|
||
Completed |
NCT03941184 -
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
|
||
Completed |
NCT03608761 -
Comparison Between Rebamipide 2% Versus Autologous Serum
|
Phase 4 | |
Active, not recruiting |
NCT04793646 -
N-acetylcysteine for Primary Sjögren's Syndrome
|
N/A |